Loading
A phase 3 trial of tarlatamab and durvalumab in lung cancer, run by PrECOG, LLC., not yet recruiting.
Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT07637513 by PrECOG, LLC., with a registry enrolment figure of 430 participants, started 2027-01 and due to reach its primary completion in 2037-11. Interventions recorded: Tarlatamab; Durvalumab. Conditions listed: Limited Stage Small-Cell Lung Cancer. Primary outcome: This phase III study has dual primary endpoints of progression-free survival (PFS) and overall survival (OS).; This phase III study has dual primary endpoints of progression-free survival (PFS) and overall survival (OS).. Lung eligibility wording from the registry: "* Patient must have histologically or cytologically confirmed Small Cell Lung Cancer (SCLC)". No results are recorded here; the registry entry is the source.
Shares Tarlatamab, Amgen, Bispecific antibodies, T-cell engagers (bispecific) and the tag lung-deep-dive.
Shares Tarlatamab, Amgen, Bispecific antibodies, T-cell engagers (bispecific) and the tag lung-deep-dive.
Shares Tarlatamab, Amgen, Bispecific antibodies, T-cell engagers (bispecific) and the tag lung-deep-dive.
Shares Tarlatamab, Amgen, Bispecific antibodies, T-cell engagers (bispecific) and the tag lung-deep-dive.
Shares Durvalumab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Limited-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Limited-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Limited-stage small-cell lung cancer, Durvalumab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.